Drug Target Review

JANUARY 26, 2024

Researchers from Columbia University and the US Department of Energy (DOE)’s Brookhaven National Laboratory have elucidated a method to produce large quantities of the receptor that the SARS-CoV-2 spike protein uses to bind to the surface of human cells.

Production 114

Production DNA Virus Protein Expression 114

Drug Target Review

SEPTEMBER 4, 2023

Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. He has over two years of experience in research and laboratory work.

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

JANUARY 13, 2021

said, “Nearly 30 years ago my laboratory at Columbia University generated the first anti-CD40-ligand mAb (5c8), discovered and characterized human CD40-ligand and elucidated the molecular basis of T cell helper function 1. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Discovery World

NOVEMBER 8, 2023

The luncheon presentation will be done by James Keck, PhD, President’s Innovation Fellow and Senior Director, Innovation and Product Development, Product Development, The Jackson Laboratory. CCO & Co-Founder, ATUM, on: “Using machine learning to predict protein expression”. Claes Gustafsson, Ph.D,

Engineering 162

Engineering Protein Expression Therapies Science 162

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

NOVEMBER 9, 2023

The luncheon presentation will be given by Hans Gerstmans, Postdoctoral Researcher, Laboratory for Biomolecular Discovery & Engineering, KU Leuven, VIB, alongside Wai Long Tam, Head of Technology Watch at VIB, Technology Watch, VIB. The session ends with two presentations and two luncheon presentations.

Engineering 130

Engineering Therapies Protein Production Science 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. based Mogrify Limited expanded its research collaboration with MRC Laboratory of Molecular Biology.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52